NEW YORK, NY / ACCESSWIRE / June 26, 2017 / Both Juno Therapeutics and Antares Pharma saw some nice gains on Friday, with Juno closing over 7%. Despite any big news on that particular day, traders are still excited over the company's positive data announced on its TRANSCEND trial of JCAR017 for Non-Hodgkin Lymphoma. Antares Pharma also saw big gains after it was revealed that an analyst at H.C. Wainright not only has a "buy" rating on the company but also a $5.00 price target.

RDI Initiates Coverage on:

Juno Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=JUNO

Antares Pharma, Inc.
https://ub.rdinvesting.com/news/?ticker=ATRS

Juno Therapeutics, Inc.'s shares closed up 7.49% on Friday with a little over 3.7 million shares traded. Earlier this month the biopharmaceutical company presented data from its TRANSCEND trial of JCAR017 at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland. JCAR017 is one of the company's main candidates in its cancer therapy pipeline and the study has aimed to evaluate the safety and pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma. President of Research and Development Sunil Agarwal M.D. commented, "We are pleased to again present TRANSCEND data, which show compelling results in the treatment of aggressive relapsed or refractory NHL. High rates of durable responses and the early survival data are especially exciting, as is the emerging safety profile. The majority of TRANSCEND patients experienced no cytokine release syndrome or neurotoxicity at all. While still early, these data suggest that JCAR017 could be administered on an outpatient basis."

Access RDI's Juno Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=JUNO

Antares Pharma, Inc.'s shares closed up 6.64% on Friday and hit a new high of $3.24 during intra-day trading. Despite the big jump in price and new high, there was no considerable news from the company to explain the move. What did happen was that Corey Davis, an analyst at H.C. Wainright, has given the stock a "buy" rating and a price target of $5.00. According to Davis, Antares shares have "rebounded strongly off multi-year lows" and that the firm believes there is still more upside as its diversified business strategy matures. The company, which has a focus on developing self-administered parenteral pharmaceutical products and technologies, may soon have an FDA decision on its Xyosted combo product, an innovation testosterone therapy. Xyosted has an FDA PDUFA date of October 20, 2017.

Access RDI's Antares Pharma Research Report at:
https://ub.rdinvesting.com/news/?ticker=ATRS

Our Actionable Research on Juno Therapeutics, Inc. (NASDAQ: JUNO) and Antares Pharma, Inc. (NASDAQ: ATRS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com